CIDEB

Across TCGA pan-cancer cohorts, CIDEB Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CIDEB data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CIDEB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CIDEB expression acts as an unfavorable survival marker.

SKCM, COAD, and CHOL are the cancer types where CIDEB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.233	0.787	.003	9	view →
COAD	DFS	Median	All	0.170	0.790	.013	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CIDEB–SKCM (OS)

Open the SKCM breakdown →